UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns
November 27, 2013 at 11:10 AM EST
In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on BioMarin Pharmaceutical (NASDAQ: BMRN ) with an Overweight rating and $87.00 price target. In the report, Piper Jaffray noted, “We are initiating, resuming or assuming coverage on 16 biotechnology companies. We believe the outlook for the